HC Wainwright reiterated their buy rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report sent to investors on Tuesday morning, The Fly reports. HC Wainwright currently has a $267.00 target price on the biotechnology company’s stock, up from their previous target price of $160.00.
A number of other analysts have also weighed in on SRPT. Piper Jaffray Companies cut their target price on shares of Sarepta Therapeutics from $208.00 to $185.00 and set an overweight rating on the stock in a research report on Tuesday. Zacks Investment Research upgraded shares of Sarepta Therapeutics from a hold rating to a buy rating and set a $130.00 target price on the stock in a research report on Wednesday, May 8th. BidaskClub lowered shares of Sarepta Therapeutics from a hold rating to a sell rating in a research report on Wednesday, August 14th. Royal Bank of Canada raised their target price on shares of Sarepta Therapeutics from $188.00 to $220.00 and gave the company an outperform rating in a research report on Monday, July 1st. Finally, Evercore ISI restated a buy rating and issued a $200.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, August 8th. One research analyst has rated the stock with a sell rating, one has given a hold rating and twenty-one have issued a buy rating to the company. Sarepta Therapeutics currently has a consensus rating of Buy and a consensus price target of $197.78.
Shares of Sarepta Therapeutics stock opened at $93.61 on Tuesday. Sarepta Therapeutics has a fifty-two week low of $90.24 and a fifty-two week high of $165.87. The company has a debt-to-equity ratio of 0.44, a quick ratio of 7.84 and a current ratio of 8.81. The company’s 50 day moving average price is $139.42 and its two-hundred day moving average price is $130.16.
In other Sarepta Therapeutics news, CEO Douglas S. Ingram purchased 16,252 shares of the company’s stock in a transaction dated Monday, August 12th. The stock was purchased at an average price of $123.07 per share, with a total value of $2,000,133.64. Following the completion of the purchase, the chief executive officer now owns 424,405 shares of the company’s stock, valued at $52,231,523.35. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Richard Barry purchased 5,000 shares of the company’s stock in a transaction dated Tuesday, August 20th. The shares were acquired at an average cost of $99.32 per share, with a total value of $496,600.00. Following the purchase, the director now directly owns 3,182,065 shares of the company’s stock, valued at approximately $316,042,695.80. The disclosure for this purchase can be found here. Insiders have bought 26,252 shares of company stock valued at $3,109,234 in the last ninety days. Insiders own 6.60% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in SRPT. Evolution Wealth Advisors LLC bought a new position in Sarepta Therapeutics during the second quarter worth $25,000. Trust Co. of Vermont raised its stake in Sarepta Therapeutics by 2,125.0% during the second quarter. Trust Co. of Vermont now owns 178 shares of the biotechnology company’s stock worth $27,000 after buying an additional 170 shares during the last quarter. Steward Partners Investment Advisory LLC bought a new position in Sarepta Therapeutics during the second quarter worth $32,000. Lindbrook Capital LLC bought a new position in Sarepta Therapeutics during the first quarter worth $35,000. Finally, Quadrant Capital Group LLC bought a new position in Sarepta Therapeutics during the first quarter worth $51,000. 93.59% of the stock is owned by hedge funds and other institutional investors.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Recommended Story: What is a Special Dividend?
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.